Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

rade 3/4 elevated total bilirubin reported among atazanavir recipients in each of the groups, respectively. There were no opportunistic infections reported in the vicriviroc groups compared to two in the control group, and no systemic malignancies reported in any of the groups in the 48- week study.

These results supported the selection of the 30 mg once-daily vicriviroc dose for use in ongoing Phase III clinical studies.

About Vicriviroc Ongoing Phase III Studies

Building on the results of the VICTOR-E1 study, Schering-Plough is currently enrolling patients in two large global Phase III clinical studies with vicriviroc administered once-daily as a single 30 mg tablet in adult treatment-experienced HIV patients with R5-type virus only.

The two ongoing Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV-Infected Treatment-Experienced Subjects), evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The optimized background therapy must include at least two drugs to which the patient's HIV is susceptible. Patients coinfected with hepatitis B or C may be included in these studies and there are no exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The two studies are currently enrolling approximately 375 patients each at more than 160 sites in North America, Latin America, Europe, Australia and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own bi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ersity College of Medicine research team led by Ya...of regulation in the cell division cycle, which co...cer begins. , Wang, an assistant professor of bi... the findings will lead to an improved ability to ...w drugs that kill cancer cells by inhibiting cell ...
(Date:11/21/2008)...l/ -- Heska Corporation,(Nasdaq: HSKA ) today a...f,Security Analysts, 12th Annual Biotech and Spec...77 Avenue of the Americas, 2nd Floor in New York, ...5 a.m. Eastern Time (7:35 a.m.,Mountain Time) and...eks,following the presentation through a link und...
(Date:11/21/2008)...antibiotic resistance from widespread use , ... with moderate to severe chronic obstructive pulmo...uency of exacerbations through a regular, low dose...The study, published in the first issue for Decemb...tical Care Medicine , found that twice-daily 250-m...
(Date:11/21/2008)...he University of Texas M. D. Anderson Cancer Cen... to eradicate breast cancer in Panama through the ...ch of the Americas today at an event with Laura Bu...n Fernandez de Torrijos, the First Lady of Panama....ve are the U.S. Department of State and Susan G. K...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3
...he treatment of many complex problems. According t...ue of Angiology if pine bark extract Pycnogenol? (...p of muscles. The reason and scientific basis beh...act improves blood flow to the muscles which speed...
...the MCD today said there was a rise in the breedin...s it launched //a special drive to check breeding ...uito breeding, responsible for the spread of the d...arious parts of the city especially in desert cool...
...ammatory drug Dicolofenec on the country's vulture...ed to withdraw licences for manufacturing it for v...director of the prominent NGO Bombay Natural Histo...sented a copy of Drug Controller General Ashwini K...
...posed to pesticides that is used for killing bugs ...son’s disease //. Parkinson's disease is a disorde... and so may affect movement, speech and posture. ...berta Frigerio and others studied 149 patients who...
Other Medicine News:Health News:A herbal delight for athletes in solving cramp and pain problems 2Health News:A herbal delight for athletes in solving cramp and pain problems 3
(Date:11/20/2008)...SE III TRIAL SHOW SIGNIFICANT, DECREASES IN P..., IN, FIBROMYALGIA PAT...ium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz Pharm...xt Brussels: UCB),announced today positive prelim...e III pivotal clinical trials of sodium oxybate (J...
(Date:11/20/2008)...Call/ -- Bionovo, Inc.,(Nasdaq: BNVI ) announce...1B,clinical trial of their lead drug candidate fo...he Society for Integrative Oncology,s Fifth Intern...any,s oral presentation was selected,as a top sco...he Best of the,SIO Session on November 20, 2008. ...
(Date:11/20/2008)...ta from a prospective,registry presented this wee...eatment with the Trellis(R) Peripheral Infusion Sy...) successfully breaks up the blood clot in most,p...ue, called isolated pharmacomechanical thrombolysi...an current catheter-directed thrombolysis,(CDT) t...
(Date:11/19/2008)...Science Corporation,researcher, Dan Tinker, prese...ual Conference in Washington, DC this week indicat...ers. The computerized brain plasticity-based,Bra...at target auditory and,language systems. The exe...ents in cognition by improving speed and accuracy ...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Using Early Stage Commercialization Activities to Build Long Term Success for the Bottom Line 8451 1Using Early Stage Commercialization Activities to Build Long Term Success for the Bottom Line 8451 2This Holiday Season Some Dream of a White Christmas The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 8449 1This Holiday Season Some Dream of a White Christmas The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 8449 2This Holiday Season Some Dream of a White Christmas The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 8449 3GeneGo Integrates With Cytoscape 2266 1GeneGo Integrates With Cytoscape 2266 2Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2264 1Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2264 2
...07 - Roche today announced,results of a small stud... treatment with Peg-Intron(R) (peginterferon alfa-... first 12 weeks, were,able to complete 12 weeks of... and ribavirin. Furthermore, 92 percent of,these p...rse of,treatment with PEGASYS. The data, which wer...
...rstCall/ -- Bristol-Myers,Squibb Company (NYSE: BM...ich showed that treatment with Baraclude (entecavi...adefovir at 48 weeks,-- a result that was also see...a from an open-label, randomized viral kinetics st...tigen (HBeAg),positive patients were presented at ...
Other Medicine Technology:Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 2Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 3Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 4Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 5Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 6Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
...um Eppendorf Style Low Binding, Graduated Pipet Ti...Pipettors.Reduces DNA and protein binding. Non-rea... completely by automation. RNAse & DNAse free. AVR...nd 10 racks/cs. AVR100 is the Cell Rack packaged 9...
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Like all Gilson disposable pipette tips, TowerPacks are available in a sterilized version. Each Sterilized TowerPack is individually wrapped in medical device-quality plastic to help protect tips fro
Medicine Products: